- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pasithea Therapeutics Corp (KTTA)
Track today's live Pasithea Therapeutics (KTTA) share price, performance and key data on this page with our current NASDAQ:KTTA stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Pasithea Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the KTTA share price, head to our technical summary section, which provides analysis on Pasithea Therapeutics share price buy/sell indicators using real-time data (or discuss the Pasithea Therapeutics (KTTA) stock price today with other investors in the Pasithea Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:KTTA share price (ISIN: US70261F2020) to enhance your trading decisions with our free investment tools and resources.
What Is the Pasithea Therapeutics Corp Share Price Today?
The Pasithea Therapeutics share price today is 0.460.
What Is the Stock Symbol for Pasithea Therapeutics Corp
The stock symbol (or 'ticker') for Pasithea Therapeutics Corp is "KTTA."
What Stock Exchange Does Pasithea Therapeutics Corp Trade On?
Pasithea Therapeutics Corp is listed and trades on the NASDAQ stock exchange.
Is Pasithea Therapeutics Corp a Good Stock to Buy?
Determining whether Pasithea Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:KTTA share price (ISIN: US70261F2020) to enhance your trading decisions with our free investment tools and resources.
What Is the Pasithea Therapeutics Corp Share Price Today?
The Pasithea Therapeutics share price today is 0.460.
What Is the Stock Symbol for Pasithea Therapeutics Corp
The stock symbol (or 'ticker') for Pasithea Therapeutics Corp is "KTTA."
What Stock Exchange Does Pasithea Therapeutics Corp Trade On?
Pasithea Therapeutics Corp is listed and trades on the NASDAQ stock exchange.
Is Pasithea Therapeutics Corp a Good Stock to Buy?
Determining whether Pasithea Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.427
0.467
52 wk Range
0.281
2.060
KTTA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.4270.467
52 wk Range
0.2812.060
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KTTA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
3.000
Upside
+552.17%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 13G Pasithea Therapeutics Corp. For: 23 June- Investing.com
- Form 13G Pasithea Therapeutics Corp. For: 23 June
- Investing.com
Form 4 Pasithea Therapeutics Corp For: 22 June- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 3.000
(+552.17% Upside)
Earnings
Latest Release
03/06/2026
EPS / Forecast
-0.12 / --
Revenue / Forecast
-- / --
Compare KTTA to Peers and Sector
Metrics to compare | KTTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKTTAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.8x | −6.9x | −0.4x | |
PEG Ratio | −0.01 | 0.65 | 0.00 | |
Price/Book | 0.3x | 4.1x | 2.6x | |
Price / LTM Sales | - | 19.8x | 3.0x | |
Upside (Analyst Target) | - | 134.4% | 56.0% | |
Fair Value Upside | Unlock | 4.8% | 9.1% | Unlock |
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Pasithea Therapeutics (NASDAQ: KTTA) Share Price Today?
The Pasithea Therapeutics stock price today is 0.460 USD.
What Stock Exchange Does Pasithea Therapeutics (KTTA) Trade On?
Pasithea Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Pasithea Therapeutics?
The stock symbol (also called a 'ticker') for Pasithea Therapeutics is "KTTA."
What Is the Current Pasithea Therapeutics Market Capitalisation?
As of today, Pasithea Therapeutics (NASDAQ: KTTA) market cap is 15.370M USD.
What Is Pasithea Therapeutics's (KTTA) Earnings Per Share (TTM)?
The Pasithea Therapeutics EPS is currently -1.571 (Trailing Twelve Months).
When Is the Next Pasithea Therapeutics Earnings Date?
Pasithea Therapeutics's next earnings report will be released on 02/09/2026.
Is KTTA a Buy or Sell From a Technical Analyst Perspective?
Based on today's Pasithea Therapeutics moving averages and other technical indicators, the daily buy/sell signal for KTTA stock is Strong Sell.
How Many Times Has Pasithea Therapeutics Stock Split?
Pasithea Therapeutics has split 1 times. (See the KTTA stock split history page for full effective split date and price information.)
How Many Employees Does Pasithea Therapeutics Have?
Pasithea Therapeutics has 5 employees, based on their latest Companies House report.
What is the current trading status of Pasithea Therapeutics (NASDAQ: KTTA)?
As of 03/08/2026, Pasithea Therapeutics (KTTA) is trading at a share price of 0.460 USD, with a previous close of 0.460 USD. The stock has fluctuated within a day range of 0.427 USD to 0.467 USD, while its 52-week range spans from 0.281 USD to 2.060 USD.
What Is Pasithea Therapeutics (KTTA) Price Target According to Analysts?
The average 12-month price target for Pasithea Therapeutics is 3.000 USD, with a high estimate of 3 USD and a low estimate of 3 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +552.17% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.